Related Experiment Video
Updated: Aug 11, 2026

MALDI Imaging Mass Spectrometry of Neuropeptides in Parkinson's Disease
Published on: February 14, 2012
Decreased striatal D2 receptor binding in non-manifesting carriers of the DYT1 dystonia mutation
1Center for Neurosciences, North Shore-Long Island Jewish Research Institute, Manhasset, NY 11030, USA.
Abstract:
To determine whether reduced striatal D2 receptor binding reported in patients with idiopathic torsion dystonia is associated with the genotype, the authors used PET and [11C]-raclopride to assess non-manifesting carriers of the DYT1 mutation. D2 receptor binding was reduced by approximately 15% in caudate and putamen (p < 0.005). These results suggest that striatal D2 binding reductions are a trait feature of the DYT1 genotype.
More Related Videos
10:41Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
06:45Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
Related Concept Videos
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson Disease ll: Pathophysiology
Huntington Disease l: Introduction
Alterations in Muscle Tone ll
Alterations in Muscle Tone lll